AstraZeneca: Neoplasms trials

The registry lists 127 Neoplasms studies with AstraZeneca as lead sponsor. 8 are open to participants now and 47 have results posted.

Phase 1 81Phase 2 27Phase 3 13Phase 4 1No phase 12(a study in two phases counts in both)

Studies

Page 1 of 2. Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast CancerRecruitingNCT07647328Phase 3
• Human ADME Study of [14C]-AZD1390Not yet recruitingNCT07643870Phase 1
• Observational Study That Will Analyse the Spread and Stratification of Lung Cancer Risk Using Artificial IntelligenceNot yet recruitingNCT07617636
• Osimertinib Combined With Chemotherapy in Patients Who Had Distant Recurrence After Adjuvant Osimertinib for EGFRm Resectable SIB-IIIA NSCLC.RecruitingNCT07279935Phase 4
• Anifrolumab Malignancy and Serious Infections StudyRecruitingNCT07000110
• AZD5305 hADME in Patients With Advanced Solid MalignanciesRecruitingNCT06713369Phase 1
• Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With DurvalumabEnrolling by invitationNCT05303532Phase 3
• A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid MalignanciesRecruitingNCT05123482Phase 1/2
• Durvalumab and Tremelimumab for Pediatric MalignanciesActive, not recruitingNCT03837899Phase 1/2Results posted
• Durvalumab Alone or in Combination With Novel Agents in Subjects With NSCLCCompletedNCT03822351Phase 2Results posted
• Neoadjuvant Durvalumab Alone or in Combination With Novel Agents in Resectable Non-Small Cell Lung CancerCompletedNCT03794544Phase 2Results posted
• Safety and Efficacy of MEDI0457 and Durvalumab in Participants With Human Papilloma Virus (HPV) Associated Recurrent/Metastatic Head and Neck CancerCompletedNCT03162224Phase 1/2Results posted
• A Phase I, Open-label Study to Assess Bioavailability of a Single Oral Dose of AZD9291 vs an IV Dose of [14C]AZD9291CompletedNCT02491944Phase 1Results posted
• A Study to Assess the Relative Bioavailability of Process Variants of Selumetinib in Healthy Male VolunteersCompletedNCT02322749Phase 1Results posted
• Study to Assess the Effect of AZD9291 on the Blood Levels of Rosuvastatin, in Patients With EGFRm+ Non-small Cell Lung CancerCompletedNCT02317016Phase 1Results posted
• A Study to Assess the Absolute Bioavailability of Oral Selumetinib in Healthy Male Volunteers.CompletedNCT02238782Phase 1Results posted
• Study in Pediatrics With Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia (pALL) or Lymphoblastic LymphomaTerminatedNCT02227108Phase 2Results posted
• Drug-Drug Interaction Study With AZD9291 and Omeprazole in Healthy VolunteersCompletedNCT02224053Phase 1Results posted
• Study to Assess the Effect of Rifampicin on Blood Levels and Safety of AZD9291, in Patients With EGFRm+ NSCLCCompletedNCT02197247Phase 1Results posted
• Study to Assess the Effect of AZD9291 on the Blood Levels of Simvastatin in Patients With EGFRm+ NSCLCCompletedNCT02197234Phase 1Results posted
• Study to Determine the Effect of Food on the Blood Levels of AZD9291 Following Oral Dosing of a Tablet Formulation in Patients With Non-Small Cell Lung CancerCompletedNCT02163733Phase 1Results posted
• Study to Assess the Effect of Itraconazole (a CYP3A4 Inhibitor) on the Pharmacokinetics of AZD9291, in Patients With EGFR Positive Non-small Cell Lung Cancer. Patients Will be Chosen From Those Who Have Already Been Prescribed an EGFR TKI Medicine (Such as Iressa or Tarceva)CompletedNCT02157883Phase 1Results posted
• To Assess Safety and Effect of Olaparib on the Pharmacokinetics of Anastrozole, Letrozole & Tamoxifen, and Their Effect on Olaparib, in Patients With Advanced Solid CancerCompletedNCT02093351Phase 1Results posted
• Study to Assess the Blood Levels and Safety of Olaparib in Patients With Advanced Solid Tumours and Normal or Impaired Kidney FunctionCompletedNCT01894256Phase 1Results posted
• Study to Assess the Blood Levels and Safety of Olaparib in Patients With Advanced Solid Tumours and Normal Liver Function or Mild or Moderate Liver ImpairmentCompletedNCT01894243Phase 1Results posted
• Investigate the Safety and Tolerability of Olaparib Tablet in Japanese Patients With Advanced Solid MalignanciesCompletedNCT01813474Phase 1Results posted
• AZD9291 First Time In Patients Ascending Dose StudyCompletedNCT01802632Phase 1/2Results posted
• Investigate the Safety and Tolerability of AZD6244 Monotherapy or + Docetaxel in Japanese Patients With Advanced Solid Malignancies or Non-Small Cell Lung CancerCompletedNCT01605916Phase 1Results posted
• A Global Study to Compare the Effects of Fulvestrant and Arimidex in a Subset of Patients With Breast Cancer.CompletedNCT01602380Phase 3Results posted
• Assess the Efficacy of AZD8931 in Combination With Paclitaxel Versus Paclitaxel Alone in Patients With Gastric CancerTerminatedNCT01579578Phase 2Results posted
• A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI0639 in Advanced Solid TumorsCompletedNCT01577745Phase 1Results posted
• Study of Anastrozole +/- AZD8931 in Postmenopausal Women With Endocrine Therapy Naive Breast CancerTerminatedNCT01151215Phase 2Results posted
• Study to Assess the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Efficacy of AZD2014CompletedNCT01026402Phase 1Results posted
• A Clinical Study Using MEDI-551 in Adult Participants With Relapsed or Refractory Advanced B-Cell MalignanciesCompletedNCT00983619Phase 1/2Results posted
• Study is Designed to Assess the Safety and Tolerability of AZD4547 at Increasing Doses in Patients With Advanced TumoursTerminatedNCT00979134Phase 1Results posted
• ZD4054 (Zibotentan) or Placebo Plus Chemotherapy in Patients With Advanced Ovarian CancerTerminatedNCT00929162Phase 2Results posted
• Phase I/II AZD8931/Paclitaxel in Treatment of Advanced Solid Tumours (Phase I) and Advanced Breast Cancer (Phase II)CompletedNCT00900627Phase 1/2Results posted
• A Dose Escalation, Dose Expansion Study to Evaluate the Safety, Tolerability, and Antitumor Activity of MEDI-575, in Subjects With Advanced Tumors.CompletedNCT00816400Phase 1Results posted
• A Dose-escalation Study to Evaluate the Safety, Tolerability, and Antitumor Activity of MEDI-573 in Subjects With Advanced Solid TumorsCompletedNCT00816361Phase 1Results posted
• Cediranib in Combination With Lomustine Chemotherapy in Recurrent GlioblastomaCompletedNCT00777153Phase 3Results posted
• AZD0530 Phase II Study in Patients With Advanced Ovarian CancerCompletedNCT00610714Phase 2Results posted
• Arimidex/Tamoxifen Neo Adjuvant Study in Premenopausal Patients With Breast Cancer Under Anti Hormonal TreatmentCompletedNCT00605267Phase 3Results posted
• Phase I/II, Open-label, Multi-center, Two Part Dose-escalation, Safety, Pharmacokinetics (PK) and Efficacy Study of AZD4877 in Patients With Acute Myelogenous Leukemia (AML)TerminatedNCT00486265Phase 1Results posted
• Cediranib (AZD2171, RECENTIN™) in Metastatic or Recurrent Renal Cell CarcinomaCompletedNCT00423332Phase 2Results posted
• The Biological Activity of Cediranib (AZD2171) in Gastro-Intestinal Stromal Tumours(GIST).CompletedNCT00385203Phase 2Results posted
• A Rollover Study for Patients Who Received Tremelimumab in Other Protocols, to Allow the Patients Access to Tremelimumab Until This Agent Becomes Commercially Available or Development is Discontinued.CompletedNCT00378482Phase 2Results posted
• Anastrozole and Fulvestrant Compared to Anastrozole as Adjuvant Treatment of Postmenopausal Patients With Breast CancerCompletedNCT00357110Phase 2Results posted
• Study of Zoladex Given Every 12 Weeks Versus Given Every Month in Advanced Breast Cancer (ABC) Pre-menopausal WomenCompletedNCT00322348Phase 2Results posted
• A Clinical Trial to Compare Efficacy and Tolerability of Fulvestrant 250mg, 250mg Plus 250mg Loading Regimen and 500mgCompletedNCT00313170Phase 2Results posted
• Effect of Food Upon Pharmacokinetics of Single Oral Dose of Cediranib (AZD2171, Recentin™)CompletedNCT00306891Phase 2Results posted
• A Clinical Trial to Compare Efficacy and Tolerability of Fulvestrant 250mg, 250mg (Plus 250mg Loading Regimen) and 500mgCompletedNCT00305448Phase 2Results posted
• A Clinical Trial to Compare Efficacy and Tolerability of Faslodex With Arimidex in Patients With Advanced Breast CancerCompletedNCT00274469Phase 2Results posted
• Study to Investigate the Management of Hypertension and Efficacy of AZD2171 in Patients With Advanced Solid TumoursCompletedNCT00264004Phase 2Results posted
• Anastrozole Monotherapy Versus Maximal Oestrogen Blockade With Anastrozole and Fulvestrant Combination TherapyCompletedNCT00256698Phase 3Results posted
• Safety Study to Evaluate FluMist in Immunocompromised ChildrenCompletedNCT00112112Phase 1Results posted
• Human ADME Study of [14C]-Ceralasertib (AZD6738) and Absolute Bioavailability of CeralasertibTerminatedNCT06754761Phase 1
• Observational Study on the Treatment of Patients With Metastatic Breast CancerCompletedNCT06676436
• A Study to Investigate the Effects of Durvalumab With Oleclumab Following Chemoradiation in Participants With Locally Advanced Unresectable Non-Small Cell Lung Cancer (LADOGA)Active, not recruitingNCT06606847Phase 2
• Small/Middle Tier Cities and County Lung Cancer Quality Improvement Project (QIP) StudyActive, not recruitingNCT06494241
• Osimertinib With Chemotherapy as First-line Therapy for EGFR Mutation-positive NSCLCActive, not recruitingNCT06376084
• A Study to Investigate Efficacy and Safety of Ceralasertib Plus Durvalumab in Participants Aged ≥ 18 Years With Advanced or Metastatic Non-small Cell Lung Cancer Whose Disease Progressed on or After Prior Anti-PD-(L)1 Therapy and Platinum-based ChemotherapyActive, not recruitingNCT05941897Phase 2
• First in Human Study of AZD9592 in Solid TumorsActive, not recruitingNCT05647122Phase 1
• Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Osimertinib (TAGRISSO) (ROSY-T)Active, not recruitingNCT05629234Phase 3
• Drug-drug Interaction Study With AZD5305 and Itraconazole in Patients With Advanced Solid MalignanciesCompletedNCT05573724Phase 1
• Descriptive Study of the Incidence of Malignancy in Severe Asthma Patients Receiving Benralizumab and Other Biologic Therapy, a Post Authorization Safety StudyCompletedNCT04991805
• Study to Determine the Prevalence of Homologous Recombination Deficiency Among Women With Newly Diagnosed, High-grade, Serous or Endometrioid Ovarian, Primary Peritoneal, and/or Fallopian Tube CancerCompletedNCT04991051
• Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)Active, not recruitingNCT04964934Phase 3
• A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced DiseaseActive, not recruitingNCT04711252Phase 3
• Absolute Bioavailability and ADME Study of Savolitinib in Healthy Male SubjectsCompletedNCT04675021Phase 1
• A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312)Active, not recruitingNCT04529772Phase 3
• Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With OlaparibActive, not recruitingNCT04421963Phase 3
• Investigating Safety, Tolerability, Efficacy and PK of Olaparib in Paediatric Patients With Solid TumoursCompletedNCT04236414Phase 1
• A Study of MEDI1191 in Sequential and Concurrent Combination With Durvalumab in Subjects With Advanced Solid TumorsCompletedNCT03946800Phase 1
• A Study to Evaluate MEDI5752 in Subjects With Advanced Solid TumorsActive, not recruitingNCT03530397Phase 1
• Expanded Access Program for Olaparib Tablets as Maintenance Therapy in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Cancer.Approved for marketingNCT03079687
• Study of Samalizumab in Patients With Advanced CancerTerminatedNCT02987504Phase 1
• Study to Assess the Effect of Osimertinib (TAGRISSO™ ) on Blood Levels of Fexofenadine in Patients With EGFRm+ NSCLCCompletedNCT02908750Phase 1
• Epidemiology of Breast Cancer in Women Based on Diagnosis Data From Oncologists and Breast Surgeons in AlgeriaCompletedNCT02733601
• National Lung Cancer Registry in Men and Women Based on Diagnosis in AlgeriaCompletedNCT02725892
• A Study to Evaluate MEDI0562 in Combination With Immune Therapeutic Agents in Adult Subjects With Advanced Solid TumorsCompletedNCT02705482Phase 1
• A Study of MEDI9197 in Subjects With Solid Tumors or CTCL and in Combination With Durvalumab and/or Palliative Radiation in Subjects With Solid TumorsTerminatedNCT02556463Phase 1
• Study to Assess the Blood Levels and Safety of AZD9291 in Patients With Advanced Solid Tumours and Normal Liver Function or Mild or Moderate Liver ImpairmentCompletedNCT02161770Phase 1
• Study to Assess the Effect of Rifampicin (CYP Inducer) on Blood Levels and Safety of Olaparib in Patients With Advanced Solid TumoursCompletedNCT01929603Phase 1
• To Determine the Effect of Food on the Pharmacokinetics of Olaparib and the Effect of Olaparib on QT Interval Following Oral Dosing of a Tablet Formulation in Patients With Advanced Solid TumoursCompletedNCT01921140Phase 1
• To Assess the Effect of Itraconazole (a CYP3A4 Inhibitor) on the Pharmacokinetics of Olaparib, and the Effect of Olaparib on QT Interval Following Oral Dosing of a Tablet Formulation to Patients With Advanced Solid TumoursCompletedNCT01900028Phase 1
• D081AC00001 Food Interaction With Olaparib Capsule in Patients With Solid TumoursCompletedNCT01851265Phase 1
• Study to Assess the Safety, Tolerability, and Pharmacokinetics of AMP-224 in Patients With Advanced CancerCompletedNCT01352884Phase 1
• Dose-escalation Study to Assess Safety, Tolerability and Pharmacokinetics of MEDI-573 in Japanese SubjectsCompletedNCT01340040Phase 1
• An Open-Label, Dose-Escalation Study of AZD2461CompletedNCT01247168Phase 1
• Study to Assess Safety and Tolerability of AZD4547 in Japanese PatientCompletedNCT01213160Phase 1
• Preliminary Anti-tumour Activity of mTor Kinase Inhibitor in Advanced TumoursWithdrawnNCT01194193Phase 1
• Open Label Prostate Cancer StudyCompletedNCT01162395Phase 1
• Study to Assess Safety, Tolerability and PK of AZD1480 in Patients With Solid TumoursTerminatedNCT01112397Phase 1
• A Study of MEDI-575 in Patients With Advanced Solid MalignanciesCompletedNCT01102400Phase 1
• Study Assessing Safety and Tolerability of AZD8931 Alone or in Combination With Paclitaxel in Japanese Patients.CompletedNCT01003158Phase 1
• Study to Assess Safety and Tolerability of AZD0530 in Combination With Carboplatin and PaclitaxelWithdrawnNCT01000896Phase 1
• Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Efficacy of Tor Kinase Inhibitor in Liver Cancer PatientsCompletedNCT00999882Phase 1
• Study to Assess the Safety and Tolerability of the Tor Kinase Inhibitor AZD8055CompletedNCT00973076Phase 1
• Safety and Tolerability Study of AZD7762 in Combination With GemcitabineTerminatedNCT00937664Phase 1
• Comparing Efficacy Between Anti-microtubule and Non-anti-microtubule as 3th Therapy After 2nd Line EGFR-TKI TherapyCompletedNCT00836160